Soligenix
SNGX
#10223
Rank
HK$0.12 B
Marketcap
HK$12.53
Share price
-1.23%
Change (1 day)
-49.67%
Change (1 year)

P/E ratio for Soligenix (SNGX)

P/E ratio as of December 2025 (TTM): -0.5062

According to Soligenix's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.506173. At the end of 2024 the company had a P/E ratio of -0.5843.

P/E ratio history for Soligenix from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-0.5843-39.16%
2023-0.9605-31.56%
2022-1.40-43.59%
2021-2.4917.06%
2020-2.12-28.67%
2019-2.98111.02%
2018-1.41-26.23%
2017-1.91-20.9%
2016-2.42-38.49%
2015-3.9327.14%
2014-3.0911.1%
2013-2.7866.18%
2012-1.68-38.56%
2011-2.73-47.61%
2010-5.21-16.71%
2009-6.25212.5%
2008-2.00-26.32%
2007-2.7147.02%
2006-1.85-38.46%
2005-3.00-34.95%
2004-4.617.74%
2003-4.28129.74%
2002-1.86108.93%
2001-0.8918

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Cleveland BioLabs
CBLI
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
8.44-1,767.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
13.3-2,731.53%๐Ÿ‡ซ๐Ÿ‡ท France
Pfizer
PFE
15.1-3,089.25%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
19.4-3,927.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-0.0045-99.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Onconova Therapeutics
ONTX
-0.9953 96.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
44.9-8,974.53%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.